Cooperative Agreement UG3DA063329
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $963K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
San Francisco, CA 94102, USA
Similar Awards
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $3,287,052 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Virogenomics Biodevelopment, Inc., a woman-owned small business in Tigard, Oregon. The award, granted in May 2025, is funding IND-enabling studies and Phase I clinical trials to advance DRHQ, a novel immunotherapeutic compound developed by Virogenomics to treat methamphetamine use disorder. The research...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded Myosin Therapeutics Inc. a $2,916,991 Project Grant on April 1, 2025 to support a first-in-human double-blind, placebo-controlled single ascending dose (SAD) Phase 1B clinical trial of their novel therapeutic agent MT-110 for reducing methamphetamine use disorder (MUD). With an estimated 4 million people in the U.S. affected by MUD and limited treatment options available, the...
- This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a clinical trial evaluating the impact of reduced methamphetamine use on various health outcomes. The $731,997 award will support a randomized, controlled 12-week trial with an additional 12-week follow-up period. The trial will assess improvements in cardiovascular health, immune function, sleep quality, and other psychosocial measures...
- This federal Project Grant award of $457,701 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to understand the pharmacodynamics of combined methamphetamine and fentanyl use. The primary objectives are to: 1) elucidate the mechanisms underlying polysubstance use disorders involving stimulants and opioids, and 2) investigate the role of the hypocretin/orexin neuropeptide system as a potential target for...
- This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports research to advance troriluzole as a potential treatment for methamphetamine use disorder (MUD), including for individuals with co-occurring MUD and opioid use disorder. The $634,048 grant, awarded on April 15, 2025, will fund a human laboratory study at the University of Kentucky Research Foundation to evaluate troriluzole's effects in people with MUD...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting Mebias Discovery Inc. in the development of a new chemical entity, MEB-1170, for the treatment of opioid use disorder (OUD). The project will complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 as a maintenance medication for OUD, as well as conduct Phase 1 clinical trials to assess the...
- This Cooperative Agreement award of $2,828,440 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a multi-site randomized clinical trial to evaluate the efficacy of the GLP-1/GIP receptor agonist Tirzepatide for smoking cessation. The trial aims to determine if this novel incretin-based therapy can increase cigarette abstinence rates and prevent post-cessation weight gain in treatment-seeking smokers. The project will be...
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $702,965 to the University of Texas Health Science Center at Houston to conduct a pilot mechanistic study on repurposing the drug semaglutide for the treatment of cocaine use disorder. The study aims to provide proof-of-concept evidence that semaglutide, a glucagon-like peptide receptor agonist, can modulate key reward-related mechanisms underlying cocaine use,...
- The National Institute on Drug Abuse (NIDA) awarded a $915,478 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Brown University to evaluate the effectiveness and safety of different methadone treatment strategies, including dosing and expanded take-home flexibilities, for patients with opioid use disorder in the era of fentanyl. The project aims to address challenges in methadone initiation and maintenance for individuals with a history of fentanyl use, as...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $608,652 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Scripps Research Institute. The purpose of this 5-year award, with a start date of September 1, 2025, is to conduct data mining and functional validation of the Systematic Characterization of Retroviral Conditions for Health (SCORCH) datasets. The research aims to elucidate the key pathogenic...